A Phase 3 interventional study of TAF and TDF in HBeAg-positive Chronic Hepatitis B, sponsored by Gilead Sciences. Completed at 160 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-10-10.
Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies in Hepatitis by Gilead Sciences — none open to participants now, none under way, none of them phase 3. Hepatitis · Gilead Sciences.
Among the 25 studies in Hepatitis by Gilead Sciences, this one has the largest enrollment of the 23 interventional ones that give a count, is one of 8 that started in 2013, is one of 9 in phase 3, and was the 20th registered.
344 studies on the registry are indexed under Hepatitis; 52 are open to participants now.
Browse Hepatitis studies →None of the 25 studies in Hepatitis by Gilead Sciences is open now. The open studies under Hepatitis, anywhere →
Of the 36 Hepatitis studies recruiting now, 23 (64%) set no upper age limit and 11 (31%) stop at 75 or younger; 6 take children under 18; 8 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 8 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 875 is above the median of 85 across 245 interventional studies indexed under Hepatitis.
Median enrollment 155 across the 23 interventional studies, 54 across the 1 observational. Of the 24 that completed or were terminated, 19 (79%) have results posted.
This tab as a report to print or save as PDF → With an account.
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 25 studies in Hepatitis by Gilead Sciences, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to compare the efficacy, safety, and tolerability of tenofovir alafenamide (TAF) versus tenofovir disoproxil fumarate (TDF) in treatment-naive and treatment-experienced adults with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B virus (HBV) infection.
This study GS-US-320-0110 is a multi-center clinical trial planned to enroll participants in multiple countries, including China. However, due to the review timeline difference in China, full enrollment was reached in the main study before China was able to participate. Therefore, details for the China cohort are registered separately (NCT02836249) on ClinicalTrials.gov as this cohort will not be part of the main study analysis.
Key Inclusion Criteria:
HBeAg-positive, chronic hepatitis B with all of the following:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TAF + TDF placebo for 96 weeks (per amendment 1 \& 2) or 144 weeks (per amendment 3).
Drug: TAF · Drug: TDF Placebo
TDF + TAF placebo for 96 weeks (per amendment 1 \& 2) or 144 weeks (per amendment 3).
Drug: TDF · Drug: TAF Placebo
All participants who complete the double-blind period (96 weeks or 144 weeks) will be eligible to receive open-label TAF until Week 384 of the study. After the end of study treatment, participants can either switch to commercially available anti-HBV treatments in their country or will be followed every 4 weeks, for up to 24 weeks off treatment (treatment-free follow-up (TFFU)) for safety assessment.
Drug: TAF
Percentage of Participants With Hepatitis B Virus (HBV) DNA < 29 IU/mL at Week 48
Time frame: Week 48
Percentage of Participants With Hepatitis B e Antigen (HBeAg) Seroconversion to Antibody Against Hepatitis B e Antigen (Anti-HBe) at Week 48
Time frame: Week 48
Percent Change From Baseline in Hip Bone Mineral Density (BMD) at Week 48
Time frame: Baseline, Week 48
Percent Change From Baseline in Spine BMD at Week 48
Time frame: Baseline, Week 48
Change From Baseline at Week 48 in Serum Creatinine
Time frame: Baseline, Week 48
Percentage of Participants With Treatment-emergent Proteinuria by Urinalysis (Dipstick) Through Week 48
Grades 1 (mild), 2 (moderate), and 3 (severe) were the highest treatment-emergent postbaseline grades for urine protein using the dipstick method.
Time frame: Up to 48 weeks
Participants were enrolled at study sites in East Asia, Europe, North America, Australia, India, and New Zealand.
| Milestone | TAF 25 mg | TDF 300 mg | TAF 25 mg to TAF 25 mg | TDF 300 mg to TAF 25 mg |
|---|---|---|---|---|
| Started | 582 | 293 | 0 | 0 |
| Completed | 515 | 253 | 0 | 0 |
| Not completed | 67 | 40 | 0 | 0 |
| Withdrew: Withdrew consent | 31 | 18 | 0 | 0 |
| Withdrew: Lost to follow-up | 8 | 6 | 0 | 0 |
| Withdrew: Investigator's discretion | 8 | 5 | 0 | 0 |
| Withdrew: Pregnancy | 9 | 2 | 0 | 0 |
| Withdrew: Non-compliance with study drug | 3 | 2 | 0 | 0 |
| Withdrew: Adverse event | 2 | 2 | 0 | 0 |
| Withdrew: Death | 2 | 1 | 0 | 0 |
| Withdrew: Lack of efficacy | 1 | 1 | 0 | 0 |
| Withdrew: Protocol-specified criteria for withdrawal | 1 | 1 | 0 | 0 |
| Withdrew: Randomized but never treated | 1 | 1 | 0 | 0 |
| Withdrew: Hbsag seroconversion | 1 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 1 | 0 | 0 |
| Milestone | TAF 25 mg | TDF 300 mg | TAF 25 mg to TAF 25 mg | TDF 300 mg to TAF 25 mg |
|---|---|---|---|---|
| Started | 0 | 0 | 514 | 253 |
| Completed | 0 | 0 | 422 | 213 |
| Not completed | 0 | 0 | 92 | 40 |
| Withdrew: Withdrew consent | 0 | 0 | 48 | 22 |
| Withdrew: Lost to follow-up | 0 | 0 | 13 | 8 |
| Withdrew: Investigator's discretion | 0 | 0 | 9 | 4 |
| Withdrew: Protocol-specified criteria for withdrawal | 0 | 0 | 5 | 4 |
| Withdrew: Adverse event | 0 | 0 | 5 | 1 |
| Withdrew: Non-compliance with study drug | 0 | 0 | 4 | 1 |
| Withdrew: Pregnancy | 0 | 0 | 5 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 2 | 0 |
| Withdrew: Hbsag seroconversion | 0 | 0 | 1 | 0 |
| percentage of participants | TAF 25 mg | TDF 300 mg |
|---|---|---|
| Percentage of Participants With Hepatitis B Virus (HBV) DNA < 29 IU/mL at Week 48 | 63.9 | 66.8 |
| percentage of participants | TAF 25 mg | TDF 300 mg |
|---|---|---|
| Percentage of Participants With Hepatitis B e Antigen (HBeAg) Seroconversion to Antibody Against Hepatitis B e Antigen (Anti-HBe) at Week 48 | 10.3 | 8.1 |
| percentage change | TAF 25 mg | TDF 300 mg |
|---|---|---|
| Percent Change From Baseline in Hip Bone Mineral Density (BMD) at Week 48 | -0.100 ± 2.2912 | -1.715 ± 2.5723 |
| percentage change | TAF 25 mg | TDF 300 mg |
|---|---|---|
| Percent Change From Baseline in Spine BMD at Week 48 | -0.417 ± 2.9343 | -2.294 ± 3.1331 |
| mg/dL | TAF 25 mg | TDF 300 mg |
|---|---|---|
| Change From Baseline at Week 48 in Serum Creatinine | 0.009 ± 0.1238 | 0.026 ± 0.0948 |
Grades 1 (mild), 2 (moderate), and 3 (severe) were the highest treatment-emergent postbaseline grades for urine protein using the dipstick method.
| percentage of participants | TAF 25 mg | TDF 300 mg |
|---|---|---|
| Grade 1 | 23.9 | 17.8 |
| Grade 2 | 3.5 | 4.5 |
| Grade 3 | 0 | 0.3 |
Collected over All-Cause Mortality: Randomization up to approximately 416 weeks; Adverse Events: First dose date up to Week 384. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Double-blind Phase: TAF 25 mg | 2/582 (0.3%) | 44/581 (7.6%) | 290/581 (49.9%) |
| Double-blind Phase: TDF 300 mg | 1/293 (0.3%) | 20/292 (6.8%) | 143/292 (49%) |
| Open-label TAF Extension Phase: TAF 25 mg to TAF 25 mg | 0/514 (0%) | 59/514 (11.5%) | 168/514 (32.7%) |
| Open-label TAF Extension Phase: TDF 300 mg to TAF 25 mg | 0/253 (0%) | 32/253 (12.6%) | 100/253 (39.5%) |
| Event | Double-blind Phase: TAF 25 mg | Double-blind Phase: TDF 300 mg | Open-label TAF Extension Phase: TAF 25 mg to TAF 25 mg | Open-label TAF Extension Phase: TDF 300 mg to TAF 25 mg |
|---|---|---|---|---|
| Hepatocellular carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/581 | 2/292 | 2/514 | 3/253 |
| Chest painGeneral disorders | 0/581 | 0/292 | 0/514 | 2/253 |
| Back painMusculoskeletal and connective tissue disorders | 1/581 | 0/292 | 1/514 | 2/253 |
| PyrexiaGeneral disorders | 1/581 | 0/292 | 3/514 | 0/253 |
| PneumoniaInfections and infestations | 1/581 | 0/292 | 3/514 | 0/253 |
| Haemolytic anaemiaBlood and lymphatic system disorders | 0/581 | 0/292 | 0/514 | 1/253 |
| Angina pectorisCardiac disorders | 1/581 | 0/292 | 0/514 | 1/253 |
| Coronary artery diseaseCardiac disorders | 0/581 | 0/292 | 2/514 | 1/253 |
| Patent ductus arteriosusCongenital, familial and genetic disorders | 0/581 | 0/292 | 0/514 | 1/253 |
| Angle closure glaucomaEye disorders | 0/581 | 0/292 | 0/514 | 1/253 |
| Event | Double-blind Phase: TAF 25 mg | Double-blind Phase: TDF 300 mg | Open-label TAF Extension Phase: TAF 25 mg to TAF 25 mg | Open-label TAF Extension Phase: TDF 300 mg to TAF 25 mg |
|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 71/581 | 29/292 | 33/514 | 13/253 |
| Upper respiratory tract infectionInfections and infestations | 70/581 | 33/292 | 32/514 | 17/253 |
| HeadacheNervous system disorders | 59/581 | 30/292 | 32/514 | 20/253 |
| CoughRespiratory, thoracic and mediastinal disorders | 48/581 | 24/292 | 15/514 | 19/253 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 39/581 | 22/292 | 24/514 | 15/253 |
| Back painMusculoskeletal and connective tissue disorders | 36/581 | 22/292 | 20/514 | 12/253 |
| DiarrhoeaGastrointestinal disorders | 35/581 | 19/292 | 13/514 | 6/253 |
| FatigueGeneral disorders | 36/581 | 14/292 | 6/514 | 5/253 |
| NauseaGastrointestinal disorders | 35/581 | 15/292 | 5/514 | 2/253 |
| HypertensionVascular disorders | 14/581 | 6/292 | 21/514 | 15/253 |
Safety Analysis Set: Participants who received at least 1 dose of study drugs.
| Age, Continuous(Years) | TAF 25 mg | TDF 300 mg | Total |
|---|---|---|---|
| Mean | 38 ± 11.0 | 38 ± 11.7 | 38 ± 11.3 |
| Age, Customized(Participants) | TAF 25 mg | TDF 300 mg | Total |
|---|---|---|---|
| < 50 years | 493 | 234 | 727 |
| >= 50 years | 88 | 58 | 146 |
| Sex: Female, Male(Participants) | TAF 25 mg | TDF 300 mg | Total |
|---|---|---|---|
| Female | 210 | 103 | 313 |
| Male | 371 | 189 | 560 |
| Ethnicity (NIH/OMB)(Participants) | TAF 25 mg | TDF 300 mg | Total |
|---|---|---|---|
| Hispanic or Latino | 2 | 1 | 3 |
| Not Hispanic or Latino | 575 | 290 | 865 |
| Unknown or Not Reported | 4 | 1 | 5 |
| Race (NIH/OMB)(Participants) | TAF 25 mg | TDF 300 mg | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 482 | 232 | 714 |
| Native Hawaiian or Other Pacific Islander | 1 | 3 | 4 |
| Black or African American | 2 | 3 | 5 |
| White | 96 | 52 | 148 |
| More than one race | 0 | 2 | 2 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | TAF 25 mg | TDF 300 mg | Total |
|---|---|---|---|
| Russia | 33 | 16 | 49 |
| Romania | 24 | 9 | 33 |
| Singapore | 7 | 2 | 9 |
| Hong Kong | 71 | 50 | 121 |
| United States | 33 | 21 | 54 |
| Japan | 35 | 11 | 46 |
| United Kingdom | 5 | 3 | 8 |
| India | 77 | 33 | 110 |
| Spain | 4 | 0 | 4 |
| New Zealand | 11 | 6 | 17 |
| Canada | 55 | 28 | 83 |
| Turkey | 15 | 11 | 26 |
| Taiwan | 54 | 29 | 83 |
| South Korea | 120 | 53 | 173 |
| Poland | 7 | 5 | 12 |
| Italy | 9 | 5 | 14 |
| Australia | 14 | 6 | 20 |
| Bulgaria | 4 | 2 | 6 |
| France | 3 | 2 | 5 |
| HBV DNA(log10 IU/mL) | TAF 25 mg | TDF 300 mg | Total |
|---|---|---|---|
| Mean | 7.6 ± 1.34 | 7.6 ± 1.41 | 7.6 ± 1.36 |
| Plasma HBV DNA Level(Participants) | TAF 25 mg | TDF 300 mg | Total |
|---|---|---|---|
| < 8 log10 IU/mL | 309 | 150 | 459 |
| ≥ 8 log10 IU/mL | 272 | 142 | 414 |
3 further baseline measures are reported on the registry.
Showing the first 100 of 160 sites across 19 countries. Choose a country and city above to see the rest.
Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gileadclinicaltrials.com/transparency-policy/
Supporting information: Study protocol, Statistical analysis plan
Time frame: 18 months after study completion
Access criteria: A secured external environment with username, password, and RSA code.
Data sharing details ↗ · www.gileadclinicaltrials.com
Ran from Sep 2013 to primary completion in Nov 2015, 26 months.
Results were first posted in Mar 2017, 1 year 4 months after primary completion. A results delay was requested in Aug 2016.
Of 23 phase 3 interventional studies under Hepatitis, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 38. This study's 26 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tenofovir alafenamide